Damora Therapeutics, Inc.

Appointment of Director

On August 6, 2026, our board of directors appointed Andrew Cheng, M.D., Ph.D. as a Class III director effective as of August 12, 2026 (the “Effective Date”). In connection with his appointment, Dr. Cheng was appointed as a member of the Compensation Committee of the board of directors.

Andrew Cheng, M.D., Ph.D. (Age 59). Dr. Cheng has served as President, Chief Executive Officer and Chairman of the Board of Avere Therapeutics, a biotechnology company, since 2026. He previously served as President and Chief Executive Officer of Akero Therapeutics, Inc. (NASDAQ: AKRO), a biotechnology company, from 2018 until its acquisition by Novo Nordisk in December 2025, where he also served on the board of directors. Prior to Akero, he spent nearly two decades at Gilead Sciences, where his last role was Chief Medical Officer. Dr. Cheng serves on the board of directors of Vera Therapeutics (NASDAQ: VERA) and he previously served as a board member at MorphoSys (NASDAQ: MOR), until its acquisition by Novartis in 2024, and Arbutus Biopharma Corporation (NASDAQ: ABUS). Dr. Cheng received his M.D. and Ph.D. from Columbia University College of Physicians and Surgeons and completed his internal medicine residency at the University of California, Los Angeles and was board certified in internal medicine.

In connection with his appointment as a director, Dr. Cheng will receive a cash retainer and an initial grant of equity awards in accordance with the Company’s non-employee director cash and equity compensation program. The equity award will be an option to purchase the lesser of (i) 40,000 Ordinary Shares or (ii) a number of Ordinary Shares determined by dividing $700,000 by the Black-Scholes value of an option to purchase one Ordinary Share on the date of grant, under the 2026 Equity Plan, with an exercise price per share equal to the closing price of the Company’s Ordinary Shares on the date of grant. This option will vest and become exercisable in equal monthly installments through the third anniversary of the date of grant, subject to Dr. Cheng’s continued service as a director through each applicable vesting date.

In connection with his appointment as a director, Dr. Cheng will enter into our standard form of indemnification agreement for directors, a copy which is filed as Exhibit 10.1 to this Quarterly Report on Form 10-Q.

There are no family relationships between Dr. Cheng and any of our executive officers or directors. There are no arrangements or understandings between Dr. Cheng and any other person pursuant to which he was appointed as one of our directors. Dr. Cheng is not a party to any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

On the Effective Date, our board of directors increased its size from six to seven members.

Rule 10b5-1 Trading Plans

During the three months ended June 30, 2026, none of the Company’s directors or officers adopted, materially modified, orterminated any contract, instruction, or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any non-Rule 10b5-1 trading arrangement.